Sign in

CIK 0000072444

  • Accelerated filer
  • Smaller reporting company

Vaxart, Inc.

Sign in to watch
Ticker
VXRT
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
591212264
Phone
+1 650-550-3500
Business address
310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2010-04-05 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Sale −1,520 $5.32 $8K 115,852
2010-04-05 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Sale −700 $5.34 $4K 115,152
2010-04-05 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Sale −200 $5.36 $1K 114,952
2010-04-05 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Sale −500 $5.37 $3K 114,452
2010-04-05 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Sale −600 $5.38 $3K 113,852
2010-04-05 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Sale −600 $5.39 $3K 113,252
2010-04-01 Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops Grant or award +24,000 53,650.1
2010-04-01 Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops Sale −250 $5.48 $1K 53,400.1
2010-04-01 Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops Sale −400 $5.48 $2K 53,000.1
2010-04-01 Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops Sale −1,300 $5.49 $7K 51,700.1
2010-04-01 Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops Other disposition −2,100 $5.49 $12K 49,600.1
2010-04-01 Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops Grant or award · Stock Option (Right to Buy) +60,000 60,000
2010-04-01 FAHIM RAAFAT E F President, CEO and CFO Grant or award +50,000 333,818.94
2010-04-01 FAHIM RAAFAT E F President, CEO and CFO Grant or award · Stock Option (Right to Buy) +125,000 125,000
2010-04-01 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Grant or award +36,000 118,500
2010-04-01 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Grant or award · Stock Option (Right to Buy) +90,000 90,000
2010-03-24 Aryeh Jason Director Sale −234 $6.24 $1K 251,883
2010-03-23 Aryeh Jason Director Sale −64,793 $6.25 $405K 252,117
2010-03-22 Aryeh Jason Director Sale −28,510 $6.24 $178K 316,910
2010-03-19 Aryeh Jason Director Sale −7,800 $5.99 $47K 345,420

Page 30 of 42 · 830 trades